JP2002529097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002529097A5 JP2002529097A5 JP2000581225A JP2000581225A JP2002529097A5 JP 2002529097 A5 JP2002529097 A5 JP 2002529097A5 JP 2000581225 A JP2000581225 A JP 2000581225A JP 2000581225 A JP2000581225 A JP 2000581225A JP 2002529097 A5 JP2002529097 A5 JP 2002529097A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- compound
- product
- medicament
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000976806 Genea <ascomycete fungus> Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9824437.9 | 1998-11-06 | ||
| GBGB9824437.9A GB9824437D0 (en) | 1998-11-06 | 1998-11-06 | Gene therapy |
| PCT/EP1999/009017 WO2000028059A1 (en) | 1998-11-06 | 1999-11-05 | Adenovirus-mediated gene therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002529097A JP2002529097A (ja) | 2002-09-10 |
| JP2002529097A5 true JP2002529097A5 (https=) | 2006-12-21 |
| JP4733833B2 JP4733833B2 (ja) | 2011-07-27 |
Family
ID=10842035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000581225A Expired - Fee Related JP4733833B2 (ja) | 1998-11-06 | 1999-11-05 | アデノウィルスを介する遺伝子治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6579855B1 (https=) |
| EP (1) | EP1135513B2 (https=) |
| JP (1) | JP4733833B2 (https=) |
| KR (1) | KR20020013473A (https=) |
| CN (1) | CN1184321C (https=) |
| AT (1) | ATE341639T1 (https=) |
| AU (1) | AU749451B2 (https=) |
| CA (1) | CA2348624C (https=) |
| CY (1) | CY1106198T1 (https=) |
| DE (1) | DE69933468T3 (https=) |
| DK (1) | DK1135513T4 (https=) |
| ES (1) | ES2273521T5 (https=) |
| GB (1) | GB9824437D0 (https=) |
| HU (1) | HUP0104046A3 (https=) |
| NO (1) | NO330776B1 (https=) |
| PL (1) | PL193076B1 (https=) |
| PT (1) | PT1135513E (https=) |
| WO (1) | WO2000028059A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0910950D0 (en) | 2009-06-24 | 2009-08-05 | Ark Therapeutics Ltd | Filtration |
| GB0916997D0 (en) | 2009-09-28 | 2009-11-11 | Ark Therapeutics Ltd | Combination therapy |
| US20130296407A1 (en) * | 2011-01-18 | 2013-11-07 | Ark Therapeutics, Ltd. | Combination Therapy for Cancer |
| GB201100804D0 (en) * | 2011-01-18 | 2011-03-02 | Ark Therapeutics Ltd | Drug combination |
| CA2863964C (en) | 2012-02-07 | 2021-10-26 | Global Bio Therapeutics Usa, Inc. | Compartmentalized method of nucleic acid delivery and compositions and uses thereof |
| US20160058888A1 (en) * | 2013-05-08 | 2016-03-03 | Gliotherapy Limited | Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir |
| WO2015021443A1 (en) | 2013-08-08 | 2015-02-12 | Global Bio Therapeutics Usa, Inc. | Clamp device for minimally invasive procedures and uses thereof |
| DE102019000490A1 (de) | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
| BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
| MX2022014239A (es) | 2020-05-12 | 2023-02-09 | Regeneron Pharma | Nuevos agonistas de il10 y metodos para su uso. |
| CN117597365A (zh) | 2021-05-04 | 2024-02-23 | 再生元制药公司 | 多特异性fgf21受体激动剂及其应用 |
| TW202321282A (zh) | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| TW202334223A (zh) | 2021-11-11 | 2023-09-01 | 美商再生元醫藥公司 | Ｃｄ２０－ｐｄ１結合分子及其使用方法 |
| EP4649088A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| EP4649092A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| IL322890A (en) | 2023-02-28 | 2025-10-01 | Regeneron Pharma | Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen |
| EP4709756A1 (en) | 2023-05-10 | 2026-03-18 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662441B2 (ja) * | 1986-02-18 | 1994-08-17 | 花王株式会社 | 抗腫瘍物質徐放性製剤 |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
-
1998
- 1998-11-06 GB GBGB9824437.9A patent/GB9824437D0/en not_active Ceased
-
1999
- 1999-11-05 WO PCT/EP1999/009017 patent/WO2000028059A1/en not_active Ceased
- 1999-11-05 KR KR1020017004945A patent/KR20020013473A/ko not_active Ceased
- 1999-11-05 AU AU13851/00A patent/AU749451B2/en not_active Ceased
- 1999-11-05 AT AT99971860T patent/ATE341639T1/de active
- 1999-11-05 PT PT99971860T patent/PT1135513E/pt unknown
- 1999-11-05 DK DK99971860.4T patent/DK1135513T4/da active
- 1999-11-05 PL PL349489A patent/PL193076B1/pl unknown
- 1999-11-05 HU HU0104046A patent/HUP0104046A3/hu not_active Application Discontinuation
- 1999-11-05 US US09/830,725 patent/US6579855B1/en not_active Expired - Lifetime
- 1999-11-05 JP JP2000581225A patent/JP4733833B2/ja not_active Expired - Fee Related
- 1999-11-05 DE DE69933468T patent/DE69933468T3/de not_active Expired - Lifetime
- 1999-11-05 ES ES99971860T patent/ES2273521T5/es not_active Expired - Lifetime
- 1999-11-05 CN CNB998129305A patent/CN1184321C/zh not_active Expired - Fee Related
- 1999-11-05 EP EP99971860A patent/EP1135513B2/en not_active Expired - Lifetime
- 1999-11-05 CA CA2348624A patent/CA2348624C/en not_active Expired - Fee Related
-
2001
- 2001-05-04 NO NO20012220A patent/NO330776B1/no not_active IP Right Cessation
-
2006
- 2006-10-13 CY CY20061101473T patent/CY1106198T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002529097A5 (https=) | ||
| CA2348624A1 (en) | Adenovirus-mediated gene therapy | |
| MY124853A (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives. | |
| ES2316567T3 (es) | Adeponectina para la regeneracion hepatica. | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| WO2000053730A3 (en) | Medical preparations for the treatment of alpha-galactosidase a deficiency | |
| JP2005532332A5 (https=) | ||
| WO2002045431A3 (en) | Genetically engineered herpes virus for the treatment of cardiovascular disease | |
| JP2002532432A5 (https=) | ||
| BR9807319A (pt) | Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos. | |
| WO1998000541A3 (en) | Methods for administration of recombinant gene delivery vehicles for treatment of human disease | |
| RU97104483A (ru) | Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2- циклопентен-1-метанола в качестве антивирусного агента | |
| JP2002530353A5 (https=) | ||
| AU2001258322B2 (en) | Formulation having mobilising activity | |
| Soria et al. | Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose | |
| WO2003084979A3 (fr) | Peptides et leur application en therapeutique | |
| Zein | Interferons in the management of viral hepatitis | |
| US20170348345A1 (en) | Combination Therapy For Cancer | |
| WO2005084387A3 (en) | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer | |
| KR19990028522A (ko) | 유전자 제제 | |
| AR004196A1 (es) | Un metodo a alta velocidad para preparar granulos esfericos que comprende un medicamento para uso farmaceutico, granulos obtenibles mediante este metodoy una bolsita que contiene dichos granulos | |
| ZA202304877B (en) | Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof | |
| Suntsova et al. | Use of romiplostim for newly diagnosed immune thrombocytopenia in children | |
| JP2005502690A5 (https=) | ||
| van der Veen et al. | Stealth® liposomal tumor necrosis factor-α in solid tumor treatment |